Background
==========

Pancreatic cancer, currently one of the most lethal human malignancies \[[@b1-medscimonit-22-3529]\], is largely refractory to conventional therapies. Peroxisome proliferator-activated receptor alpha (PPARα), a member of the PPAR family \[[@b2-medscimonit-22-3529]\], regulating tumorigenesis \[[@b3-medscimonit-22-3529]\], is a ligand-activated transcription factor \[[@b4-medscimonit-22-3529]\]. Caspase-3 is encoded by the CASP3 gene \[[@b5-medscimonit-22-3529]\], as a potential therapeutic target for cancer patients \[[@b6-medscimonit-22-3529]\] and plays key roles in the growth stimulation.

(−)-Epigallocatechin-3-gallate (EGCG) (C~22~H~18~O~11~; [Figure 1A](#f1-medscimonit-22-3529){ref-type="fig"}), found in green tea \[[@b7-medscimonit-22-3529]\], which is widely consumed in China \[[@b8-medscimonit-22-3529]\], is one of the most abundant and powerful catechins \[[@b9-medscimonit-22-3529]\] in cancer prevention and treatment. (1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl) cyclohexane carboxamide (Y-27632) (C~14~H~21~N~3~O; [Figure 1B](#f1-medscimonit-22-3529){ref-type="fig"}), a selective inhibitor of rho-associated protein kinase 1 (ROCK1) \[[@b10-medscimonit-22-3529]\], is widely used in treating cardiovascular disease \[[@b11-medscimonit-22-3529]\], inflammation \[[@b12-medscimonit-22-3529]\], and cancer \[[@b13-medscimonit-22-3529]\]. Although Y-27632 \[[@b14-medscimonit-22-3529]--[@b16-medscimonit-22-3529]\] and EGCG \[[@b17-medscimonit-22-3529]--[@b19-medscimonit-22-3529]\] inhibit the growth of many cancer cells, whether the efficacy of Y-27632 increases the sensitivity of PANC-1 cells to EGCG is not yet clear. The present study hypothesized that the combination of Y-27632 and EGCG would reveal additive inhibitory effects *in vitro*.

In the present study, the capacity of Y-27632 to sensitize PANC-1 cells to the effects of EGCG in regulating cell proliferation and migration was investigated. Furthermore, the expression of PPARα *mRNA* and caspase-3 *mRNA* in EGCG and Y-27632 alone, and in EGCG combined with Y-27632 on PANC-1 cells, was examined.

Material and Methods
====================

Cell culture
------------

PANC-1 cells (SIBCB, Shanghai, China) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco BRL, MD, USA) (15) supplemented with 10% fetal bovine serum (Gibco BRL, MD, USA) and penicillin (100 U/mL)--streptomycin (100 mg/mL) (Gibco BRL, MD, USA) in a humidified atmosphere containing 5% CO~2~ and 95% air at 37°C.

Cell proliferation assay
------------------------

PANC-1 cells (1×10^6^/well) were seeded into 96-well plates (Corning, NY, USA). These cells were then treated with dimethyl sulfoxide (DMSO) (control) as well as different concentrations (20, 40, 60, and 80 μg/mL) of EGCG (NICPBP, Beijing, China) for 48 h. In addition, PANC-1 cells were treated separately with DMSO (control), 60 μg/mL EGCG, 20 μM Y-27632, and EGCG combined with Y-27632 (60 μg/mL EGCG + 20 μM Y-27632) for 48 h. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) \[[@b16-medscimonit-22-3529]\] as described in a previous study. The absorbance (*A*) of each hole in the 96-well plate was determined at 475 nm using a microplate reader, using the formula:
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Hoechst 33258 staining
----------------------

PANC-1 cells were treated separately with DMSO (control), 60 μg/mL EGCG, 20 μM Y-27632, and 60 μg/mL EGCG + 20 μM Y-27632 for 48 h. After washing with phosphate-buffered saline (Gibco BRL), the fixed PANC-1 cells were stained with 10 -μg/mL Hoechst 33258 (Beyotime Institute of Biotechnology, Jiangsu, China) \[[@b17-medscimonit-22-3529]\] for 10 min at room temperature.

Transwell migration assay
-------------------------

PANC-1 cells (1×10^6^/well) were placed in the upper chamber of a transwell filter. Drugs (DMSO, 60 μg/mL EGCG, 20 μM Y-27632, and 60 μg/mL EGCG + 20 μM Y-27632) were added separately into the upper chamber and PANC-1 cells were incubated for 10 h. After fixation and 0.1% crystal violet staining, PANC-1 cells were counted and the cell migration inhibition rate \[[@b18-medscimonit-22-3529]\] of each group was calculated.

Quantitative real-time reverse transcription-polymerase chain reaction
----------------------------------------------------------------------

PANC-1 cells were treated separately with DMSO (control), 60 μg/mL EGCG, 20 μM Y-27632, and 60 μg/mL EGCG + 20 μM Y-27632 for 48 h. Quantitative real-time polymerase chain reaction (RT-qPCR) \[[@b19-medscimonit-22-3529]\] was used to observe the expression of PPARα mRNA and caspase-3 mRNA of these groups. The primer pairs \[glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), PPARα, and caspase-3\] were synthesized by Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. (Shanghai, China). The primer pairs included the following: forward: 5′-AGAAGGCTGGGGCTCATTTG-3′ and reverse: 5′-AGGGGCCATCCACAGTCTTC-3′ for *GAPDH* (258 bp); forward: 5′-TTCGCAATCCATCGGCGAG-3′ and reverse: 5′-CCACAGGATAAGTCACCGAGG-3′ for PPARα (146 bp). Forward: 5′-CATGGAAGCGAATCAATGGACT-3′ and reverse: 5′-CTGTACCAGACCGAGATGTCA-3′ for caspase-3 (139 bp). *GAPDH* was used as an internal control to evaluate the relative expression of PPARα. RT-qPCR reagents were purchased from TIANGEN Biotech (Beijing) Co., Ltd. (Beijing, China). Relative mRNA was calculated using the formula: 2−ΔΔCt \[[@b20-medscimonit-22-3529],[@b21-medscimonit-22-3529]\].

Statistical analysis
--------------------

Data are shown as mean ± standard deviation. Statistical comparisons were performed using SPSS version 18.0 software (22). *P*\<0.05 was considered to be significant \[[@b23-medscimonit-22-3529],[@b24-medscimonit-22-3529]\].

Results
=======

Y-27632 augments the antiproliferative effect of EGCG in PANC-1 cells
---------------------------------------------------------------------

The effect of EGCG and Y-27632 on the PANC-1 cell proliferation was evaluated using the CCK-8 assay. Different concentrations of EGCG (20, 40, 60, and 80 μg/mL) inhibited cell viability in a dose-dependent manner ([Figure 1C](#f1-medscimonit-22-3529){ref-type="fig"}). EGCG (60 μg/mL) inhibited PANC-1 cell viability by 69% ([Figure 1D](#f1-medscimonit-22-3529){ref-type="fig"}). Y-27632 (20 μM) inhibited PANC-1 cell viability by 17% ([Figure 1D](#f1-medscimonit-22-3529){ref-type="fig"}), and 60 μg/mL EGCG + 20 μM Y-27632 inhibited PANC-1 cell viability by 82% ([Figure 1D](#f1-medscimonit-22-3529){ref-type="fig"}). These results suggest that 20 μM Y-27632 enhanced the sensitivity of PANC-1 cells to 60 μg/mL EGCG and suppressed cell proliferation.

Y-27632 improved the anti-migration and apoptosis effect of EGCG in PANC-1 cells
--------------------------------------------------------------------------------

The effect of 60 μg/mL EGCG on the PANC-1 cell migration in the presence of 20 μM Y-27632 was evaluated using transwell migration assays ([Figure 2A](#f2-medscimonit-22-3529){ref-type="fig"}). Following treatment with 60 μg/mL EGCG + 20 μM Y-27632, the cell migration significantly decreased compared with that of the untreated PANC-1 control and the cells treated with 20 μM Y-27632 or 60 μg/mL EGCG alone ([Figure 2B](#f2-medscimonit-22-3529){ref-type="fig"}). These data suggest that PANC-1 cell migration is inhibited by treatment with 60 μg/mL EGCG + 20 μM Y-27632. Under Hoechst 33258 staining ([Figure 2C](#f2-medscimonit-22-3529){ref-type="fig"}), the normal PANC-1 cells without 60 μg/mL EGCG and 20 μM Y-27632 intervention were dark blue (control), but early apoptotic nuclei due to chromosomal collapse were stained bright blue in the 60 μg/mL EGCG and 20 μM Y-27632 treatment groups ([Figure 2C](#f2-medscimonit-22-3529){ref-type="fig"}), and were easily distinguished from the normal cells. Also, the number of bright blue-stained nuclei increased ([Figure 2C](#f2-medscimonit-22-3529){ref-type="fig"}) in the 60 μg/mL EGCG + 20 μM Y-27632 treatment group.

Combination of Y-27632 and EGCG increased the expression of PPARα mRNA and caspase-3 mRNA
-----------------------------------------------------------------------------------------

The expression of PPARα *mRNA* and caspase-3 *mRNA* was determined by RT-qPCR. The amplification and melting curves of PPARα and caspase-3 are shown in [Figure 3A, 3B](#f3-medscimonit-22-3529){ref-type="fig"}. Significant changes in the expression of PPARα *mRNA* and caspase-3 *mRNA* were observed in PANC-1 cells treated with 60 μg/mL EGCG or 20 μM Y-27632 alone, and 60 μg/mL EGCG + 20 μM Y-27632. Treatment with 20 μM Y-27632 + 60 μg/mL EGCG caused a sharp increase in the expression of PPARα *mRNA* and caspase-3 *mRNA* compared with the levels detected following treatment with 60 μg/mL EGCG or 20 μM Y-27632 alone ([Figure 3C](#f3-medscimonit-22-3529){ref-type="fig"}).

Discussion
==========

Our study demonstrated that Y-27632 sensitized the PANC-1 cells to the inhibitory effects of EGCG on cell proliferation and migration. Furthermore, the combination of Y-27632 and EGCG promoted apoptosis of the PANC-1 cells. The results also indicate that the Y-27632-induced sensitization is related to the increased expression of PPARα mRNA and caspase-3 mRNA.

This study, using the CCK-8 assay, evaluated the probable effect of different concentrations of EGCG (20, 40, 60, and 80 μg/mL) on PANC-1 cells. The results are in agreement with a previous study \[[@b25-medscimonit-22-3529]\], which showed that EGCG (20--80 μg/mL) inhibited the proliferation of PANC-1 cells in a dose-dependent manner. The results also showed that at 48 h, Y-27632 enhanced the sensitivity of PANC-1 cells to EGCG and suppressed the proliferation of PANC-1 cells.

In the present study, using transwell migration assays and Hoechst 33258 staining, the effect of 20 μM Y-27632 combined with 60 μg/mL EGCG on the PANC-1 cell migration and apoptosis was evaluated. The results also showed that 20 μM Y-27632 enhanced the anti-migration effect of 60 μg/mL EGCG on PANC-1 cells when treated for 48 h. Furthermore, the effects of 60 μg/mL EGCG in regulating apoptosis of PANC-1 cells enhanced when treated with 20 μM Y-27632 + 60 μg/mL EGCG.

Tumor growth and metastasis depend on angiogenesis \[[@b26-medscimonit-22-3529],[@b27-medscimonit-22-3529]\], and gene expression profiling of PPARα has been used in several studies \[[@b28-medscimonit-22-3529],[@b29-medscimonit-22-3529]\], but a very few studies included pancreatic cancer. When PANC-1 cells were exposed to EGCG \[[@b30-medscimonit-22-3529]\], the expression of PPARα, a direct negative regulator of heme oxygenase (HO-1) activation by EGCG \[[@b31-medscimonit-22-3529]\], which confers cell susceptibility to EGCG, increased at the protein level in a dose-dependent manner. EGCG induces apoptosis and inhibits the growth of PANC-1 tumors \[[@b32-medscimonit-22-3529]\] and activates caspase-3 is a dose-dependent manner. Therefore, the capacity of Y-27632 to sensitize PANC-1 cells to EGCG by activated PPARα mRNA and caspase-3 mRNA expression were investigated.

Conclusions
===========

The combination of EGCG and Y-27632 significantly increased the expression of PPARα mRNA and caspase-3 mRNA in PANC-1 cells. These data suggest that Y-27632 sensitizes PANC-1 cells to EGCG by increasing the expression of PPARα mRNA and caspase-3 mRNA. The synergistic effect of the combination of EGCG and Y-27632 on PANC-1 provides new and useful information for its application in pancreatic cancer therapy.
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![Effect of the combination of (−)-epigallocatechin-3-gallate (EGCG) and (1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl) cyclohexane carboxamide (Y-27632) on PANC-1 cell proliferation. (**A, B**) Chemical structure of EGCG (C~22~H~18~O~11~) and Y-27632 (C~14~H~21~N~3~O). (**C**) Different concentrations of EGCG (20, 40, 60, and 80 μg/mL) inhibited cell viability in a dose-dependent manner. The effect of EGCG and Y-27632 on the PANC-1 cell proliferation was evaluated by CCK-8 assay. (**D**) PANC-1 cells were treated separately with DMSO (control), 60 μg/mL EGCG, 20 μM Y-27632, and 60 μg/mL EGCG + 20 μM Y-27632 for 48 h. Data represent mean ± standard error of mean, *n* = 3. Compared with control, \*\* *P*\<0.01. Compared with EGCG, \* *P*\<0.05.](medscimonit-22-3529-g001){#f1-medscimonit-22-3529}

![Effect of the combination of EGCG and Y-27632 on PANC-1 cell migration and apoptosis. PANC-1 cells were treated separately with DMSO (control), 60 μg/mL EGCG, 20 μM Y-27632, and 60 μg/mL EGCG + 20 μM Y-27632 for 48 h. (**A**) The effect of 60 μg/mL EGCG on the PANC-1 cell migration in the presence of 20 μM Y-27632 was evaluated using transwell migration assays. (**B**) Data represent mean ± SEM, *n*=3. Compared with control, \* *P*\<0.05, \*\* *P*\<0.01. Compared with control, Y-27632, or EGCG, \*\*\* *P*\<0.01. (**C**) Apoptosis of EGCG and Y-27632 in PANC-1 cells was determined by Hoechst 33258 staining.](medscimonit-22-3529-g002){#f2-medscimonit-22-3529}

![The combination of EGCG and Y-27632 increased the expression of PPARα *mRNA* and caspase-3 *mRNA*. PANC-1 cells were treated with DMSO (control), EGCG (60 μg/ml EGCG), or Y-27632 (20 μM Y-27632), and EGCG combined with Y-27632 (60 μg/ml EGCG + 20 μM Y-27632) for 48 h. The expression of PPARα *mRNA* and caspase-3 *mRNA* was analyzed by qRT-PCR. (**A**) The amplification curves of PPARα and caspase-3. (**B**) The melting curves of PPARα and caspase-3. (**C**) The relative gene expression of PPARα *mRNA* and caspase-3 *mRNA* in each group. Data represent mean ± SEM, *n*=3. Treatment with 20 μM Y-27632 + 60 μg/mL EGCG (compared with control, \* *P*\<0.05) caused a sharp increase in the expression of PPARα mRNA and caspase-3 *mRNA* compared with the levels detected following treatment with 60 μg/mL EGCG or 20 μM Y-27632 alone (compared with 20 μM Y-27632 + 60 μg/mL EGCG, \* *P*\<0.05).](medscimonit-22-3529-g003){#f3-medscimonit-22-3529}

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection
